Pfizer (PFE)

39.38 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (5/1/19 *Est.)
- Annual Meeting (4/25/2019)

Latest Headlines

Pfizer (PFE). Eli Lilly & Co. (NYSE:LLY) Report Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis April 18, 2019 5:06 PM - StreetInsider Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis April 18, 2019 5:05 PM - BizWire Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders April 18, 2019 2:00 PM - BizWire Merck (MRK), Lilly (LLY), Pfizer (PFE) Weakness Continues as Biotech Shares Get Hit Again April 18, 2019 10:23 AM - StreetInsider Merck (MRK), Pfizer (PFE) Lilly (LLY) Shares Decline Amid Biotech Weakness April 17, 2019 10:26 AM - StreetInsider Form 4 PFIZER INC For: Apr 15 Filed by: ROGERS DAWN April 16, 2019 7:20 PM - SEC Filing Form 4 PFIZER INC For: Apr 15 Filed by: YOUNG JOHN D April 16, 2019 7:19 PM - SEC Filing Form 4 PFIZER INC For: Apr 15 Filed by: BOURLA ALBERT April 16, 2019 7:18 PM - SEC Filing Form 4 PFIZER INC For: Apr 15 Filed by: JOHNSON RADY A April 16, 2019 7:18 PM - SEC Filing Pfizer (PFE) option implied volatility flat as shares near record high April 16, 2019 10:20 AM - StreetInsider Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults A April 13, 2019 4:00 AM - BizWire Form 4 PFIZER INC For: Apr 10 Filed by: YOUNG JOHN D April 11, 2019 4:07 PM - SEC Filing Form 4 PFIZER INC For: Apr 10 Filed by: BOURLA ALBERT April 11, 2019 4:07 PM - SEC Filing Form 4 PFIZER INC For: Apr 10 Filed by: JOHNSON RADY A April 11, 2019 4:06 PM - SEC Filing Form 4 PFIZER INC For: Apr 10 Filed by: ROGERS DAWN April 11, 2019 4:06 PM - SEC Filing GlaxoSmithKline (GSK) and Pfizer (PFE) announce FDA approval of ViiV Healthcare's Dovato for treatment-naïve HIV-1 adults April 8, 2019 4:54 PM - StreetInsider US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults April 8, 2019 4:49 PM - BizWire Form PX14A6G PFIZER INC Filed by: SISTERS OF ST FRANCIS OF PHILADELPHIA April 8, 2019 10:36 AM - SEC Filing Pfizer (PFE) Announces FDA Approval of IBRANCE for Treatment of Men with HR+, HER2- Metastatic Breast Cancer April 4, 2019 2:58 PM - StreetInsider U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer April 4, 2019 2:57 PM - BizWire AM Best Affirms Credit Ratings of Blue Whale Re Ltd. April 4, 2019 10:04 AM - BizWire Pfizer (PFE) option implied volatility at lower end of range April 3, 2019 11:10 AM - StreetInsider Pfizer (PFE) Announces VIZIMPRO Receives MAA in EU for First-Line Treatment of Adult Patients with EGFR-Mutated NSCLC April 3, 2019 9:43 AM - StreetInsider VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer April 3, 2019 9:42 AM - BizWire Pfizer (PFE) call put ratio 2.8 calls to 1 put April 3, 2019 5:13 AM - StreetInsider Form 4 PFIZER INC For: Mar 29 Filed by: BOURLA ALBERT April 2, 2019 3:07 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: JOHNSON RADY A April 2, 2019 3:07 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: ROGERS DAWN April 2, 2019 3:07 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: YOUNG JOHN D April 2, 2019 3:07 PM - SEC Filing Form 4 PFIZER INC For: Apr 01 Filed by: MACKENZIE ALEXANDER R April 2, 2019 3:06 PM - SEC Filing Sangamo/Pfizer Data Competitive, But BioMarin (BMRN) is 'Meaningfully Ahead in Development' - Baird April 2, 2019 12:45 PM - StreetInsider Form DEFA14A PFIZER INC April 2, 2019 12:25 PM - SEC Filing Pfizer (PFE) option implied volatility at low end of range April 2, 2019 10:19 AM - StreetInsider Pre-Open Stock Movers 04/02: (ADMA) (SGMO) (RIOT) Higher; (APYX) (EFOI) (WBA) Lower (more...) April 2, 2019 9:24 AM - StreetInsider Sangamo Therapeutics (SGMO) Reports Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data April 2, 2019 7:06 AM - StreetInsider Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy April 2, 2019 7:01 AM - StreetInsider Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy April 2, 2019 7:00 AM - PR NewsWire Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy April 2, 2019 7:00 AM - BizWire Form 4 PFIZER INC For: Mar 29 Filed by: SMITH JAMES C April 1, 2019 7:01 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: KILTS JAMES M April 1, 2019 7:01 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: NARAYEN SHANTANU April 1, 2019 7:01 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: Echevarria Joseph April 1, 2019 7:01 PM - SEC Filing Bank of America Merrill Lynch Releases Top 10 US Ideas for 2Q April 1, 2019 7:56 AM - StreetInsider Pfizer (PFE) PT Raised to $48 at BofA/Merrill Lynch Ahead of Orphan Drug Catalyst April 1, 2019 6:46 AM - StreetInsider SpringWorks Therapeutics Completes $125 Million Series B Financing April 1, 2019 6:30 AM - BizWire NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Establishing Itself as a Trailblazer in Breakthrough Cancer Treatments March 29, 2019 9:00 AM - StreetInsider The EIU's Index of Cancer Preparedness reveals huge gaps in health system readiness and governance March 28, 2019 6:55 AM - StreetInsider Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy March 27, 2019 9:00 AM - StreetInsider S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion March 25, 2019 10:53 AM - PR NewsWire Form PX14A6G PFIZER INC Filed by: Trinity Health Corp March 21, 2019 3:22 PM - SEC Filing Merck KGaA and Pfizer (PFE) Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer March 20, 2019 12:00 PM - StreetInsider Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer March 20, 2019 11:59 AM - PR NewsWire Pfizer (PFE) Buys 15% Stake and Option to Acquire Gene Therapy Company Vivet Therapeutics March 20, 2019 6:46 AM - StreetInsider Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics March 20, 2019 6:45 AM - BizWire Pfizer (PFE), Merck KGaA Report Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer March 20, 2019 6:09 AM - StreetInsider Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer March 19, 2019 7:15 PM - PR NewsWire Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts March 19, 2019 10:00 AM - BizWire Form 4 PFIZER INC For: Mar 15 Filed by: ROGERS DAWN March 18, 2019 6:38 PM - SEC Filing Form 4 PFIZER INC For: Mar 15 Filed by: YOUNG JOHN D March 18, 2019 6:38 PM - SEC Filing Form 4 PFIZER INC For: Mar 15 Filed by: JOHNSON RADY A March 18, 2019 6:38 PM - SEC Filing Form 4 PFIZER INC For: Mar 15 Filed by: BOURLA ALBERT March 18, 2019 6:38 PM - SEC Filing AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Corona March 17, 2019 11:45 AM - BizWire Form CT ORDER PFIZER INC March 15, 2019 4:01 PM - SEC Filing Form DEFA14A PFIZER INC March 14, 2019 3:14 PM - SEC Filing Form DEF 14A PFIZER INC For: Apr 25 March 14, 2019 3:11 PM - SEC Filing Merck (MRK) Wins IPR Challenge to Pfizer (PFE) Patent on Vaccine - Bloomberg March 13, 2019 10:27 AM - StreetInsider Pfizer (PFE) call put ratio 3 calls to 1 put with focus on March 41.50 and May 43 calls March 12, 2019 12:55 PM - StreetInsider Pfizer (PFE) Reports FDA Approval of Oncology Biosimilar TRAZIMERA (trastuzumab-qyyp) March 12, 2019 6:20 AM - StreetInsider U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1 March 11, 2019 7:37 PM - BizWire Form 8-K PFIZER INC For: Mar 11 March 11, 2019 5:12 PM - SEC Filing ViiV Heathcare Highlights Positive, 48-Week Data from ATLAS & FLAIR Pivotal Phase III Studies of Cabotegravir and Rilpivirine in Adults Living with HIV-1 Infection March 7, 2019 3:16 PM - StreetInsider ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three March 7, 2019 1:54 PM - BizWire Form 8-K PFIZER INC For: Mar 04 March 6, 2019 4:55 PM - SEC Filing Form 424B5 PFIZER INC March 6, 2019 4:19 PM - SEC Filing Form 4 PFIZER INC For: Mar 04 Filed by: READ IAN C March 6, 2019 4:04 PM - SEC Filing Form 4 PFIZER INC For: Mar 04 Filed by: READ IAN C March 6, 2019 4:04 PM - SEC Filing Form 4 PFIZER INC For: Mar 04 Filed by: SUSMAN SALLY March 6, 2019 3:30 PM - SEC Filing Form 4 PFIZER INC For: Mar 04 Filed by: SUSMAN SALLY March 6, 2019 3:30 PM - SEC Filing Form 25-NSE PFIZER INC Filed by: NEW YORK STOCK EXCHANGE LLC March 6, 2019 2:47 PM - SEC Filing Form 4 PFIZER INC For: Mar 04 Filed by: ROGERS DAWN March 5, 2019 4:57 PM - SEC Filing Form 4 PFIZER INC For: Mar 01 Filed by: Dolsten Mikael March 5, 2019 4:57 PM - SEC Filing AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes March 5, 2019 10:05 AM - PR NewsWire Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference March 5, 2019 10:00 AM - BizWire Form FWP PFIZER INC Filed by: PFIZER INC March 5, 2019 6:11 AM - SEC Filing Pfizer (PFE) Prices $5B Debt Offering Consisting of Five Tranches of Notes March 5, 2019 5:52 AM - StreetInsider Pfizer Prices $5,000,000,000 Debt Offering March 4, 2019 8:57 PM - BizWire Form 424B3 PFIZER INC March 4, 2019 8:23 AM - SEC Filing BioXcel Therapeutics (BTAI) Announces Addition of Merck KGaA and Pfizer to Clinical Collaboration with Nektar March 4, 2019 8:09 AM - StreetInsider BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer March 4, 2019 8:02 AM - Globe NewsWire BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer March 4, 2019 8:00 AM - StreetInsider Form 4 PFIZER INC For: Feb 27 Filed by: YOUNG JOHN D March 1, 2019 7:48 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: SUSMAN SALLY March 1, 2019 7:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: ROGERS DAWN March 1, 2019 7:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: READ IAN C March 1, 2019 7:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: MACKENZIE ALEXANDER R March 1, 2019 7:38 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: LANKLER DOUGLAS M March 1, 2019 7:38 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: Lewis-Hall Freda C March 1, 2019 7:38 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: JOHNSON RADY A March 1, 2019 7:38 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: Hwang Angela March 1, 2019 7:38 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: GOETTLER MICHAEL March 1, 2019 7:37 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: Dolsten Mikael March 1, 2019 7:30 PM - SEC Filing Form 4 PFIZER INC For: Feb 28 Filed by: Fonseca Lidia March 1, 2019 7:30 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: CANGIALOSI LORETTA V March 1, 2019 7:30 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: DAMELIO FRANK A March 1, 2019 7:30 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: BOURLA ALBERT March 1, 2019 7:30 PM - SEC Filing Pfizer (PFE) Receives Positive CHMP Opinion for LORVIQUA for Certain Adult Patients with Previously-Treated ALK-Positive Advanced NSCLC March 1, 2019 8:36 AM - StreetInsider Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer March 1, 2019 8:35 AM - BizWire Form 10-K PFIZER INC For: Dec 31 February 28, 2019 2:40 PM - SEC Filing Pfizer (PFE) Announces Serotypes Included in 20VPnC Being Investigated for Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older February 28, 2019 8:07 AM - StreetInsider Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older February 28, 2019 8:00 AM - BizWire Form 4 PFIZER INC For: Feb 23 Filed by: READ IAN C February 26, 2019 8:19 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: Dolsten Mikael February 26, 2019 8:18 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: BOURLA ALBERT February 26, 2019 7:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: DAMELIO FRANK A February 26, 2019 7:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: Lewis-Hall Freda C February 26, 2019 7:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: SUSMAN SALLY February 26, 2019 7:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: YOUNG JOHN D February 26, 2019 7:46 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: JOHNSON RADY A February 26, 2019 7:46 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: LANKLER DOUGLAS M February 26, 2019 7:46 PM - SEC Filing Form 4 PFIZER INC For: Feb 25 Filed by: Hwang Angela February 26, 2019 7:12 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: ROGERS DAWN February 26, 2019 7:12 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: GOETTLER MICHAEL February 26, 2019 7:12 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: MACKENZIE ALEXANDER R February 26, 2019 7:11 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: CANGIALOSI LORETTA V February 26, 2019 7:11 PM - SEC Filing Grassley, Wyden Deliver Opening Remarks in Drug Pricing Hearing - Bloomberg February 26, 2019 10:40 AM - StreetInsider UBS Reinstates Pfizer (PFE) at Neutral February 25, 2019 7:04 AM - StreetInsider Roche 'steps up' for gene therapy with $4.3 billion Spark bet February 25, 2019 4:04 AM - StreetInsider Novartis (NVS) Rumored to Be in Talks to Acquire Amarin (AMRN) - Source February 22, 2019 9:59 AM - StreetInsider ICON Reports Fourth Quarter and Full Year 2018 Results February 20, 2019 4:15 PM - BizWire Citi Resumes Pfizer (PFE) at Neutral February 19, 2019 4:27 PM - StreetInsider Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials February 19, 2019 10:30 AM - BizWire Pfizer (PFE) Receives European Approval for ZIRABEV, Biosimilar to Avastin February 19, 2019 9:33 AM - StreetInsider Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®* February 19, 2019 9:32 AM - BizWire UPDATE: Pfizer (PFE) to Provide $15M Milestone Payment to Gliknik Inc. Following Clinical Progress with PF-06755347, Previously Known As GL-2045 February 19, 2019 8:32 AM - StreetInsider Gliknik To Receive $15 Million Milestone Payment From Pfizer Inc. Following Clinical Progress With PF-06755347, Previously Known As GL-2045 February 19, 2019 8:30 AM - PR NewsWire Pfizer (PFE) and Lilly (LLY) Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain February 19, 2019 6:51 AM - StreetInsider Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain February 19, 2019 6:45 AM - PR NewsWire Merck (MRK) Reports Pivotal Phase III Data for BAVENCIO (avelumab) Plus INLYTA (axitinib) in Advanced RCC Published in New England Journal of Medicine (Earlier) February 19, 2019 5:54 AM - StreetInsider Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine February 16, 2019 5:14 PM - PR NewsWire Form SC 13G PFIZER INC Filed by: STATE STREET CORP February 14, 2019 10:05 AM - SEC Filing Form 4 PFIZER INC For: Feb 11 Filed by: YOUNG JOHN D February 12, 2019 5:52 PM - SEC Filing Form 4 PFIZER INC For: Feb 11 Filed by: JOHNSON RADY A February 12, 2019 5:52 PM - SEC Filing Form 4 PFIZER INC For: Feb 11 Filed by: ROGERS DAWN February 12, 2019 5:52 PM - SEC Filing Form 4 PFIZER INC For: Feb 11 Filed by: BOURLA ALBERT February 12, 2019 5:52 PM - SEC Filing EMD Seron, Pfizer (PFE) Announce FDA Accepted sBLA and Granted Priority Review for BAVENCIO Plus INLYTA for Treatment of Advanced RCC February 11, 2019 5:45 PM - StreetInsider FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma February 11, 2019 5:44 PM - PR NewsWire Bristol-Myers Squibb (BMY) Announces Opdivo Plus Low-Dose Yervoy Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC February 11, 2019 5:05 PM - StreetInsider Pfizer Inc. (PFE) and Astellas Announce Phase 3 ARCHES Trial Shows XTANDI Significantly Improved Radiographic PFS in Men with Metastatic Hormone-Sensitive Prostate Cancer February 11, 2019 5:01 PM - StreetInsider Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer February 11, 2019 5:00 PM - PR NewsWire Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer February 11, 2019 5:00 PM - BizWire Form SC 13G/A PFIZER INC Filed by: VANGUARD GROUP INC February 11, 2019 2:48 PM - SEC Filing Form 4 PFIZER INC For: Feb 04 Filed by: DAMELIO FRANK A February 6, 2019 4:19 PM - SEC Filing Form SC 13G/A PFIZER INC Filed by: BlackRock Inc. February 6, 2019 3:10 PM - SEC Filing Pfizer (PFE) option implied volatility flat into President Trump State of Union Address February 4, 2019 6:12 AM - StreetInsider Form 4 PFIZER INC For: Jan 31 Filed by: Dolsten Mikael February 1, 2019 7:29 PM - SEC Filing Form 4 PFIZER INC For: Jan 30 Filed by: LANKLER DOUGLAS M February 1, 2019 7:22 PM - SEC Filing Pfizer (PFE) Reports Positive CHMP Opinion for Vizimpro (dacomitinib) Positive CHMP Opinion for Vizimpro (dacomitinib) for 1st-Line Treatment of Adult Patients February 1, 2019 9:21 AM - StreetInsider Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mu February 1, 2019 9:17 AM - BizWire Pfizer (PFE) Risk/Reward Seems Favorable, But Not Enough for Upgrade - BMO January 31, 2019 12:21 PM - StreetInsider Argus Upgrades Pfizer (PFE) to Buy January 31, 2019 6:51 AM - StreetInsider Credit Suisse Upgrades Pfizer (PFE) to Outperform January 31, 2019 4:54 AM - StreetInsider Pfizer (PFE) PT Lowered to $45 at BofA/Merrill Lynch January 30, 2019 6:09 AM - StreetInsider Pfizer (PFE) Read-Through Positive for Eidos Therapeutics (EIDX) - Leerink January 29, 2019 2:51 PM - StreetInsider Pfizer (PFE) CEO: Currently Focused on Smaller Deals - Bloomberg January 29, 2019 10:23 AM - StreetInsider Pfizer (PFE) Sees Red-to-Green Reversal January 29, 2019 9:54 AM - StreetInsider Pre-Open Stock Movers 01/29: (SANM) (DDD) (WWD) Higher; (GME) (HOG) (RMBS) Lower (more...) January 29, 2019 9:16 AM - StreetInsider Form 8-K PFIZER INC For: Jan 29 January 29, 2019 8:50 AM - SEC Filing Pfizer (PFE) Tops Q4 EPS by 1c, FY EPS Guidance Misses Consensus January 29, 2019 6:46 AM - StreetInsider PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS January 29, 2019 6:45 AM - BizWire Pfizer (PFE), Lilly (LLY) Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain January 29, 2019 6:34 AM - StreetInsider Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain January 29, 2019 6:30 AM - BizWire Pfizer (PFE) option implied volatility increases on more calls than puts into EPS January 28, 2019 5:37 AM - StreetInsider Pfizer (PFE) call put ratio 1.95 call to 1 put into Tuesday EPS January 25, 2019 10:46 AM - StreetInsider Pfizer (PFE) weekly option implied volatility bid dinto EPS January 25, 2019 5:36 AM - StreetInsider UBS Downgrades Pfizer (PFE) to Neutral January 23, 2019 5:41 AM - StreetInsider Exclusive: Private equity firms circling Nestle's skin health business - sources January 21, 2019 11:06 AM - StreetInsider GSK Chairman Hampton to step down ahead of split January 21, 2019 2:15 AM - StreetInsider Full Article List